Nuvectis Pharma Inc. has announced the successful completion of a clinical drug-drug interaction $(DDI)$ study in healthy volunteers for their investigational drug NXP900. The study aimed to determine whether NXP900 acts as an inducer of the enzyme CYP3A, classifying its induction as weak, moderate, or strong according to the International Council for Harmonization M12 guidelines. The results indicated that NXP900 is a weak inhibitor of CYP3A, increasing the concentration of Midazolam, a known CYP3A sensitive substrate, by less than two-fold. No serious or severe adverse events were reported, with diarrhea and non-infection related increases in white blood cell counts being the most common mild to moderate adverse events. These findings support the potential use of NXP900 in combination with leading EGFR and ALK inhibitors for the treatment of non-small cell lung cancer. The results of the study were presented, and Nuvectis plans to advance NXP900 into the Phase 1b program in the coming weeks.